{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:04:07Z","timestamp":1790795047534,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1053\/j.semnuclmed.2024.03.006","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T20:06:20Z","timestamp":1713211580000},"page":"530-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled"],"prefix":"10.1053","volume":"54","author":[{"given":"John","family":"Buscombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-4167","authenticated-orcid":false,"given":"Jaroslaw","family":"Cwikla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Marie","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Navalkissoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3174-1391","authenticated-orcid":false,"given":"Dominic","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0001","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7861\/clinmedicine.17-5-449","article-title":"Selective internal radiation therapy for liver tumours","volume":"17","author":"Sundram","year":"2017","journal-title":"Clin Med"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0002","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00259-002-0965-4","article-title":"A new way in targeting intracerebral tumours with 90Y labelled radiopeptides","volume":"29","author":"Buscombe","year":"2002","journal-title":"Eur J Nuc Med Mol Imag"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0003","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1148\/radiology.168.2.2839867","article-title":"Hepatic artery injection of I-131-labeled lipiodol. Part II. Preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastases","volume":"168","author":"Bretagne","year":"1988","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0004","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/1097-0142(19951201)76:11<2202::AID-CNCR2820761105>3.0.CO;2-8","article-title":"Epirubicin-lipiodol chemotherapy versus 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma","volume":"7","author":"Bhattacharya","year":"1995","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0005","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.108.060558","article-title":"Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer","volume":"50","author":"Marelli","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0006","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ijrobp.2007.05.009","article-title":"L Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study","volume":"69","author":"Bernal","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0007","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/j.semnuclmed.2007.10.006","article-title":"International atomic energy agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study","volume":"38","author":"Bernal","year":"2008","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0008","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1053\/j.gastro.2004.09.034","article-title":"Yttrium-90 microspheres for the treatment of hepatocellular carcinoma","volume":"127","author":"Geschwind","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0009","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1023\/A:1013569329846","article-title":"Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer","volume":"12","author":"Gray","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1055\/s-0041-1735569","article-title":"Post Yttrium-90 imaging","volume":"38","author":"Rice","year":"2021","journal-title":"Semin Intervent Radiol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0011","first-page":"56","article-title":"Post radioembolization yttrium-90 PET\/CT: part 1 diagnostic reporting","volume":"3","author":"Kao","year":"2013","journal-title":"ENJMMI Res"},{"issue":"2","key":"10.1053\/j.semnuclmed.2024.03.006_bib0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jso.20141","article-title":"Randomised phase 2 trial of SIR-Spheres plus fluorouracil\/leucovorin chemotherapy versus fluorouracil\/leucovorin chemotherapy alone in advanced colorectal cancer","volume":"88","author":"Van Hazel","year":"2004","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2024.03.006_bib0013","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","article-title":"Line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre randomised phase 3 trials","volume":"18","author":"Wasan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0014","doi-asserted-by":"crossref","first-page":"e636","DOI":"10.1016\/S1470-2045(17)30811-2","article-title":"Adequate SIRT activity dose is as important as adequate chemotherapy dose","volume":"18","author":"Braat","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0015","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S1470-2045(17)30589-2","article-title":"Selective internal radiotherapy in advanced colorectal cancer: only for right-sided tumours","volume":"18","author":"Schmoll","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.semnuclmed.2024.03.006_bib0016","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1016\/j.clcc.2018.06.001","article-title":"Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies","volume":"17","author":"Gibbs","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0017","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial","volume":"39","author":"Mulcahy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.semnuclmed.2024.03.006_bib0018","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.03.006_bib0019","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clon.2018.09.002","article-title":"Analysis of a national programme for selective internal radiation therapy for colorectal cancer liver metastases","volume":"31","author":"White","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.03.006_bib0020","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1080\/13696998.2020.1839273","article-title":"A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK","volume":"23","author":"Brennan","year":"2020","journal-title":"J Med Econ"},{"issue":"1","key":"10.1053\/j.semnuclmed.2024.03.006_bib0021","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00270-020-02642-y","article-title":"Clinical application of trans-arterial radioembolization in hepatic malignancies in Europe: first results from the prospective multicentre observational study CIRSE registry for SIR-spheres therapy (CIRT)","volume":"44","author":"Helmberger","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0022","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00259-013-2395-x","article-title":"Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept","volume":"40","author":"Garin","year":"2013","journal-title":"Eur J Nuc Med Med Imag"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0023","first-page":"132","article-title":"Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis","volume":"30","author":"Ozkan","year":"2015","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0024","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00259-015-3210-7","article-title":"Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis","volume":"43","author":"Edeline","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1053\/j.semnuclmed.2024.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0026","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1200\/JCO.21.01839","article-title":"Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III","volume":"39","author":"Mulcahy","year":"2021","journal-title":"Trial J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0027","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1186\/s12885-016-2868-y","article-title":"Single administration of selective internal radiation therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial","volume":"16","author":"Gandhi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0028","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejso.2014.09.007","article-title":"Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis","volume":"41","author":"Al-Adra","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejrad.2018.01.012","article-title":"Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: a systematic review","volume":"100","author":"Jia","year":"2018","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210200","article-title":"Selective internal radiation therapy for hepatic metastases of uveal melanoma: a systematic review","volume":"95","author":"Alexander","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0031","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.3390\/cancers15204942","article-title":"Selective internal radiotherapy (SIRT) and chemosaturation percutaneous hepatic perfusion (CS-PHP) for metastasized uveal melanoma: a retrospective comparative study","volume":"15","author":"BE Klob","year":"2023","journal-title":"Cancer (Basel)"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0032","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.jvir.2018.07.006","article-title":"Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after Yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma","volume":"29","author":"Allimant","year":"2018","journal-title":"J Vasc Interv Radio"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0033","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2967\/jnumed.117.197194","article-title":"Efficacy of radioembolization with 166Ho-microspheres in salvage patients with liver metastases a phase 2 study","volume":"59","author":"Prince","year":"2017","journal-title":"J Nucm Med"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0034","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00259-019-04460-y","article-title":"The superior predictive value of 166 Ho scout compared with 99mTc macro-aggregated albumin prior to 166Ho microspheres radioembolization in patients with liver metasteses","volume":"47","author":"Smits","year":"2020","journal-title":"Eur J Nuc Med Med Imaging"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1088\/0031-9155\/59\/1\/119","article-title":"Three-dimensional personalized dosimetry for 188Re liver selective internal radiation therapy based on quantitative post-treatment SPECT studies","volume":"59","author":"Shchebinin","year":"2014","journal-title":"Phys Med Biol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0036","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.apradiso.2005.01.001","article-title":"A kit for labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine","volume":"62","author":"Wunderlich","year":"2005","journal-title":"Appl Radiat Isot"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0037","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0969-8043(99)00093-7","article-title":"Preparation and biodistribution of rhenium-188 labeled albumin microspheres B 20: a promising new agent for radiotherapy","volume":"52","author":"Wunderlich","year":"2000","journal-title":"Appl Radiat Isot"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0038","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/jjco\/hym137","article-title":"Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization","volume":"37","author":"Liepe","year":"2007","journal-title":"Jpn J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0039","first-page":"1407","article-title":"Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases","volume":"46","author":"Liepe","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0040","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.12659\/MSM.890480","article-title":"Initial study of radiological and clinical efficacy radioembolization using 188Re-Human Serum Albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers","volume":"20","author":"Nowicki","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0041","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s00270-015-1128-x","article-title":"Safety of radioembolization with (90)Yttrium resin microspheres depending on coiling or no-coiling of aberrant\/high-risk vessels","volume":"38","author":"Paprottka","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0042","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12325-022-02323-x","article-title":"Advances in delivery of selective internal radiation therapy (SIRT): economic and logistical effects of same-stay work-up and procedure in the treatment of unresectable liver tumors in England","volume":"40","author":"Pollock","year":"2023","journal-title":"Adv Ther"},{"key":"10.1053\/j.semnuclmed.2024.03.006_bib0043","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1007\/s00270-017-1712-3","article-title":"Evaluation of visualization using a 50\/50 (contrast media\/glucose 5% solution) technique for radioembolization as an alternative to a standard sandwich technique","volume":"40","author":"Paprottka","year":"2017","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982400031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982400031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T10:01:21Z","timestamp":1722679281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000129982400031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S000129982400031X"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.03.006","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}